Table 1.
Included Studies
| Authors | Year | Size | Follow-up (months) | Mean age (years) | Males (%) | Cervical (%) | Open (%) | Surgery (%) | Complete (%) | MPS regimen | Within 8 h (%) | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Randomized, controlled trials | ||||||||||||
| Bracken et al.6–8 | 1990/ 1992 | 333 | 6, 12 | NR | 86 | NR | 1 | 99 | 62 | NASCIS-II | 45 | Motor scores, adverse events |
| Otani et al.38 | 1994 | 117 | 6 | NR | NR | NR | NR | NR | NR | NASCIS-II | 100 | Motor scores, adverse events |
| Pointillart et al.39 | 2000 | 52 | 12 | 30 | 90 | NR | 0 | NR | 45 | NASCIS-II | 100 | Motor scores, adverse events |
| Matsumoto et al.40 | 2001 | 46 | 24 | 61 | 91 | 100 | 0 | 0 | 33 | NASCIS-II | 100 | Adverse events |
| Observational studies | ||||||||||||
| Prendergast et al.51 | 1994 | 54 | 2 | 36 | 80 | NR | 57 | NR | 46 | NASCIS-II | NR | Motor scores, adverse events |
| Gäbler et al.41 | 1995 | 144 | >12 | 39 | 74 | 39 | NR | 100 | 42 | NASCIS-II | 100 | Frankel ≥1, adverse events |
| George et al.53 | 1995 | 145 | <1 | 34 | 77 | 55 | 9 | 68 | 64 | NASCIS-II | NR | Adverse events |
| Gerhart et al.42 | 1995 | 278 | NR | NR | NR | 55 | 6 | NR | NR | NASCIS-II | NR | Frankel ≥1 |
| Yokota et al.52 | 1995 | 38 | <1 | 37 | 87 | 63 | NR | 61 | NR | NASCIS-II | 100 | Motor scores, adverse events |
| Levy et al.43 | 1996 | 236 | 6 | 26 | 94 | 22 | 100 | 7 | 55 | NASCIS-II | 100 | Frankel ≥1, adverse events |
| Heary et al.44 | 1997 | 224 | 56 | 26 | 91 | 30 | 100 | 15 | 75 | NASCIS-II | 100 | Motor scores, Frankel ≥1, adverse events |
| Gerndt et al.45 | 1997 | 140 | NR | 32 | 77 | 56 | 0 | 77 | NR | NASCIS-II | 100 | Adverse events |
| Pollard et al.46 | 2003 | 304 | 24 | NR | NR | 100 | NR | 78 | 0 | NASCIS-II | NR | Motor scores |
| Tsutsumi et al.47 | 2006 | 70 | 6 | 51 | 89 | 100 | NR | NR | 61 | NASCIS-II | 100 | Motor scores, adverse events |
| Suberviola et al.48 | 2008 | 82 | <1 | 42 | 84 | 54 | NR | 21 | 54 | NASCIS-II | 100 | Frankel ≥1, adverse events |
| Ito et al.49 | 2009 | 79 | 3 | 58 | 80 | 100 | NR | 72 | 27 | NASCIS-II | 100 | Motor scores, AIS ≥1, adverse events |
| Aomar Millan et al.54 | 2011 | 96 | 6 | 36 | 79 | NR | NR | NR | 47 | NASCIS-II | 100 | Adverse events |
| Chikuda et al.19 | 2014 | 1624 | <1 | 61 | 79 | 100 | NR | 23 | NR | “High-dose” | NR | Adverse events |
| Khan et al.20 | 2014 | 350 | NR | 44 | 76 | 68 | NR | 100 | 43 | NASCIS-II | 100 | Adverse events |
| Sribnick et al.50 | 2014 | 15 | 22 | 37 | 60 | 100 | NR | 100 | 60 | “High-dose” | NR | AIS ≥1, adverse events |
| Evaniew et al.1 | 2015 | 88 | 4 | 45 | 88 | 73 | NR | 86 | 45 | NASCIS-II | 100 | Motor scores, adverse events |
MPS, methylprednisolone; NR, not reported; NASCIS-II, Second National Spinal Cord Injury Study; AIS, ASIA Impairment Scale.